Product
SARS-CoV-2 Bivalent mRNA Vaccine
Aliases
LVRNA021
2 clinical trials
1 indication
Indication
COVID-19Clinical trial
Randomized, Blinded, Positive and Placebo-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) Booster Vaccination in People 18 Years of Age and Older Who Have Received SARS-CoV-2 Vaccine.Status: Active (not recruiting), Estimated PCD: 2023-11-30
Clinical trial
Randomized, Blinded, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) in Participants Aged 18 Years and Older Who Have Received SARS-CoV-2 VaccineStatus: Active (not recruiting), Estimated PCD: 2023-09-28